<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1485">
  <stage>Registered</stage>
  <submitdate>23/02/2007</submitdate>
  <approvaldate>23/02/2007</approvaldate>
  <nctid>NCT00440063</nctid>
  <trial_identification>
    <studytitle>A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.</studytitle>
    <scientifictitle>A Randomized Study to Compare the Safety and Effectiveness of Two Monitoring Schedules to Maintain Hemoglobin Levels and Iron Parameters in Patients With Renal Anemia Receiving NeoRecormon</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ML20828</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - epoetin beta [NeoRecormon]

Treatment: drugs: epoetin beta [NeoRecormon]


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of patients achieving target Hb within 20 weeks.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: % of patients exceeding upper Hb target; % who fail to reach target Hb; median time to achieve Hb target; dose of NeoRecormon required to meet target Hb concentration; % who maintain target iron parameters. Safety: AEs, SAEs.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult patients, 18-80 years of age;

          -  stage 3-4 chronic kidney disease (eGFR 15-60mL/min);

          -  Hb &lt;100g/L, TSAT&gt;=20%, and ferritin &gt;=100 mcg/L at screening.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  anticipating to go on renal replacement therapy;

          -  anticipating a living related-donor kidney transplant, or a prior recipient of a
             kidney transplant;

          -  uncontrolled hypertension;

          -  congestive heart failure;

          -  active bleeding or red blood cell transfusions in 8 weeks prior to screening;
             systematic hematological disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Gosford</hospital>
    <hospital> - Herston</hospital>
    <hospital> - Liverpool</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Perth</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Tasmania</hospital>
    <hospital> - Woolloongabba</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Gosford</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Liverpool</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Tasmania</postcode>
    <postcode> - Woolloongabba</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will determine whether 8 weekly monitoring of hemoglobin and iron parameters in
      the correction phase of NeoRecormon therapy in patients with renal anemia is as safe and
      effective as 4 weekly monitoring. Patients with chronic kidney disease will receive
      NeoRecormon at a dose aimed at achieving and maintaining a Hb level of 110-130g/L. They will
      be randomized into one of two schedules for monitoring hemoglobin levels and iron parameters,
      either 4 weekly or 8 weekly. The anticipated time on study treatment is 3-12 months, and the
      target sample size is 100-500 inidividuals.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00440063</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>